Hemato Oncology Testing - Global Strategic Business Report

Global Hemato Oncology Testing Market to Reach $14.2 Billion by 2030

The global market for Hemato Oncology Testing estimated at US$3.1 Billion in the year 2022, is projected to reach a revised size of US$14.2 Billion by 2030, growing at a CAGR of 20.9% over the analysis period 2022-2030. Services, one of the segments analyzed in the report, is projected to record 19.7% CAGR and reach US$8.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Assay Kits segment is readjusted to a revised 22.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $845.7 Million, While China is Forecast to Grow at 27.2% CAGR

The Hemato Oncology Testing market in the U.S. is estimated at US$845.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 27.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.5% and 18.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 16.2% CAGR.

Select Competitors (Total 36 Featured) -

• Abbott Laboratories
• Adaptive Biotechnologies
• Archerdx, Inc.
• Arup Laboratories, Inc.
• Asuragen, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Illumina, Inc.
• Invivoscribe, Inc.
• Molecularmd (Subsidiary of Icon PLC)
• Qiagen N.V.
• Sanofi SA
• Thermo Fisher Scientific, Inc.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year